Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

An Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for sickle ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...